Company / Operating Cash Flow
Esperion Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$13.1M
FY2025
5-year range
-$263.8M / -$13.1M
FY2021-FY2025
Trend
+44.6%
vs FY2024
Sector context
#83 of 216
Health Care
What the data says
At -$13M, Esperion Therapeutics, Inc.'s operating cash flow ranks #83 of 216 in the Health Care sector. Operating Cash Flow has increased for 4 consecutive years, from -$264M in FY2021 to -$13M in FY2025.
Based on SEC 10-K filings.
-$13M in FY2025.
Improved from -$135M to -$13M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#83 of 216 in Health CareTop 38% of 216This company -$13.1M Sector average $658.7M
▼
-102.0% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s operating cash flow has grown for 4 consecutive years.
- In FY2025, operating cash flow increased 44.6% year-over-year.
- Ranks #83 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$13.1M | +44.6% |
| FY2024 | -$23.7M | +82.5% |
| FY2023 | -$135.5M | +22.5% |
| FY2022 | -$174.8M | +33.7% |
| FY2021 | -$263.8M | -209.7% |
| FY2020 | -$85.2M | -21.1% |
| FY2019 | -$70.3M | +52.7% |
| FY2018 | -$148.6M | -13.2% |
| FY2017 | -$131.3M | -175.1% |
| FY2016 | -$47.7M | -25.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026